Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Climb Bio, Inc. - Common Stock
(NQ:
CLYM
)
4.200
+0.390 (+10.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Climb Bio, Inc. - Common Stock
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 25, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
November 03, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
October 21, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
October 17, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
October 01, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
September 29, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
September 04, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
August 25, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at Upcoming September 2025 Investor Conferences
August 25, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
June 18, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 14, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
April 01, 2025
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
March 27, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
March 25, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
February 25, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
February 24, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
January 09, 2025
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to be Added to the Nasdaq Biotechnology Index
December 19, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
November 11, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
October 31, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
October 15, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
October 11, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
October 04, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Climb Bio to Host Virtual Investor Event on October 15, 2024
October 03, 2024
From
Climb Bio, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
